Trial purpose
Long-term follow-up
Tumor type
Multi-Cancer
Age
18+
Trial acronym
LITESPARK-043
Clinical summary
Summary
Researchers are looking for new ways to treat advanced solid tumours and von Hippel-Lindau (VHL)-related tumors:
- Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery
- Solid tumours are cancers mostly in body organs and tissues, not in the blood or other body liquids
- VHL-related tumours are tumours caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer
Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumours grow and survive.
This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.
Conditions
This trial is treating people with advanced solid cancers or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study
Eligibility
Inclusion
The main inclusion criteria include but are not limited to the following:
- Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study.
Exclusion
The main exclusion criteria include but are not limited to the following:
- Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable.
- Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll.
Inclusion
- You have previously participated in a certain specific clinical trial.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov, EU Clinical Trials Register *. View further details about this trial on the registry via the links below:
- NCT07405164 *
- 2025-524160-38-00 *
- 6482-043; U1111-1325-4582; MK-6482-043; JRCT2061260008; MK6482-043
Trial sponsor
Merck Sharp & Dohme LLC
Scientific Title
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information